Progen - Cellgate

Progen is a NASDAQ listed, Australia-based company focused in small molecule therapeutics for cancer.

CellGate was a California based, venture backed company with oncology assets based on epigenetic and poly amine inhibitions.

Burrill & Company’s Role

The Merchant Banking Group was exclusively retained by Progen to help expand the company’s product pipeline, and clinical/regulatory expertise in the United States via M&A

A dedicated team provided the following services:

• Defined clear search criteria for companies that would best meet Progen’s strategic objectives
  
• Identified and discreetly approached potential candidates



• Won transaction support from senior management team and BOD
  
• Assisted in due diligence
• Negotiated and closed the transaction